Abstract
Roivant Sciences Ltd. will report fiscal results on May 20, 2026 Pre-Market; this preview summarizes consensus revenue, margin and EPS expectations, last quarter’s results, and analyst views from January 1, 2026 to May 13, 2026.
Market Forecast
Consensus points to current-quarter revenue of 3.82 million US dollars, implying a 92.94% year-over-year decline; EBIT is estimated at a loss of 310.39 million US dollars and EPS at -0.345, with year-over-year changes of -43.32% and -12.16%, respectively. The company has not guided gross profit margin or net profit margin for the quarter within the available dataset, and adjusted EPS consensus is -0.345 year over year. The main business remains concentrated in product revenue and licensing/other; management emphasis this quarter centers on product contribution and any new licensing proceeds. The most promising driver among reported lines is product revenue at 20.94 million US dollars last quarter; year-over-year growth was not disclosed in the dataset.
Last Quarter Review
Roivant Sciences Ltd. posted last quarter revenue of 2.00 million US dollars; gross margin and net profit margin were not disclosed, GAAP net profit attributable to the parent company was a loss of 266.00 million US dollars, and adjusted EPS was -0.38 with a year-over-year change of -265.22%. Quarter-on-quarter net profit growth rate was -134.23%, indicating a wider loss compared with the prior quarter. The business mix showed 20.94 million US dollars from product revenue and 3.85 million US dollars from licensing, milestone, and other revenue in the last reported period.
Current Quarter Outlook
Main Business: Commercial and Collaboration Revenue
Consensus data suggest that the dominant revenue contributors are product sales and collaboration-related income such as licensing and milestones. Given the 92.94% year-over-year revenue decline in the current quarter estimate, the reported quarter is likely to see minimal recognized collaboration revenue and potentially lower net product sales contributions on an accounting basis. The EBIT loss estimate of 310.39 million US dollars implies continued elevated operating expenses linked to R&D and commercialization, and the EPS estimate of -0.345 reflects the ongoing investment cycle.
Most Promising Business: Product Revenue
Product revenue was disclosed at 20.94 million US dollars in the last reported period, making it the largest identifiable line item in the revenue breakdown. Even with a conservative assumption for the upcoming quarter, this franchise remains the most tangible near-term monetization avenue among reported categories. The quarter’s sharp year-over-year revenue decline estimate implies timing effects and variability in recognizing licensing or milestone income; should any milestone receipts materialize, revenue could deviate noticeably from current expectations.
Stock Price Drivers This Quarter
The primary swing factor is the realization of any licensing or milestone revenue, which historically introduces quarter-to-quarter volatility and can profoundly affect reported revenue and margins. Pipeline disclosures and trial updates can influence sentiment and implied future cash flows, interacting with the expected operating loss profile to drive valuation resets. Operating expense discipline and R&D timing will shape the magnitude of the EBIT loss relative to estimates, with any variance quickly reflected in EPS and share reaction.
Analyst Opinions
Among recent published views, bullish opinions dominate. One example cites Guggenheim maintaining a Buy rating, accompanied by a 30.00 US dollars price target; another view from H.C. Wainwright also maintained a Buy, with a 23.00 US dollars price target. These positive stances emphasize the company’s optionality from business development and pipeline catalysts, while acknowledging near-term revenue volatility. The prevailing bullish camp argues that the current valuation already embeds sizable R&D investment and modest near-term sales, leaving upside if milestones or pipeline progress outpace expectations in the current quarter.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments